Phaseline

Targets › HBB

HBB (Hemoglobin subunit beta): drug programs, companies and trials

5 programs from 5 companies in 5 trials: 4 Phase 1, 1 Phase 3; Hematology; next expected readout Dec 2026.

Involved in oxygen transport from the lung to the various peripheral tissues..; FUNCTION: LVV-hemorphin-7 potentiates the activity of bradykinin, causing a decrease in blood pressure.; FUNCTION: [Spinorphin]: Functions as an endogenous inhibitor of enkephalin-degrading enzymes such as DPP3, and as a selective antagonist of the P2RX3 receptor which is involved in pain signaling, these properties implicate it as a…. (UniProt, P68871)

Open in Phaseline: the race on HBB, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Genetix BiotherapeuticsLovotibeglogene Autotemcel (bb1111)
Hemoglobin beta chain exogenous gene
HBBPhase 3Sickle Cell DiseaseMay 2027
Shenzhen Hemogenβ-globin restored autologous hematopoietic stem cells (HGI-001)
Lentiviral-transduced CD34+ HSCs with LentiHBBT87Q delivering functional β-globin gene
HBBPhase 1Β-thalassemiaDec 2026
San Rocco TherapeuticsAutologous CD34+ cells transduced with TNS9.3.55
Lentiviral vector encoding normal human β-globin gene for ex vivo transduction of autologo
HBBPhase 1Confirmed Diagnosis of ß-thalassemia MajorJul 2027
Children's Hospital of PhiladelphiaALS20
lentiviral vector delivering beta globin gene
HBBPhase 1Beta-ThalassemiaDec 2027
Mark Walters, MDCRISPR_SCD001
CRISPR/Cas9-edited hematopoietic stem progenitor cells (CD34+) with sickle allele modifica
HBBPhase 1Sickle Cell DiseaseMar 2030

Conditions

Sickle Cell Disease (2) Beta-Thalassemia (1) Β-thalassemia (1) Confirmed Diagnosis of ß-thalassemia Major (1)

Modalities

other (3), protein or peptide (1)

Companies

Children's Hospital of Philadelphia (1) Mark Walters, MD (1) Shenzhen Hemogen (1) Genetix Biotherapeutics (1) San Rocco Therapeutics (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.